A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Key facts

Study ID

NCT06934226

Run by

Janssen Research & Development, LLC

People needed

752

Starts

2025-04-15

Expected to finish

2027-08-20

Last updated by the study team

2026-07-31

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
• Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
• Total psoriasis area and severity index (PASI) >=12 at screening and baseline
• Total investigator global assessment (IGA) >=3 at screening and baseline
• Candidate for phototherapy or systemic treatment for plaque psoriasis

You may not qualify if…

• Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
• Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
• Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
• Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
• Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

Where it is running

• California Dermatology & Clinical Research Institute — Encinitas, California, United States
• T Joseph Raoof Md Inc — Encino, California, United States
• First OC Dermatology — Fountain Valley, California, United States
• Dermatologist Medical Group of North County, Inc. — Oceanside, California, United States
• NorCal Clinical Research — Rocklin, California, United States
• Integrative Skin Science and Research — Sacramento, California, United States
• MedDerm Associates — San Diego, California, United States
• Southern California Dermatology — Santa Ana, California, United States
• Olive View-UCLA Education & Research Institute — Sylmar, California, United States
• University of Conn Health Center — Farmington, Connecticut, United States
• Driven Research LLC — Miami, Florida, United States
• Bioclinical Research Alliance Inc. — Miami, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Forcare Clinical Research Inc — Tampa, Florida, United States
• Hamilton Research LLC — Alpharetta, Georgia, United States
• Northshore Medical Group — Skokie, Illinois, United States
• Indiana Clinical Trial Center — Plainfield, Indiana, United States
• University of Iowa — Iowa City, Iowa, United States
• Equity Medical — Bowling Green, Kentucky, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Metro Boston Clinical Partners — Brighton, Massachusetts, United States
• The Derm Institute of West Michigan — Caledonia, Michigan, United States
• Henry Ford Hospital — Detroit, Michigan, United States
• Hamzavi Dermatology — Fort Gratiot, Michigan, United States
• Cahaba Research Inc — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.